Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.

[1]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.

[2]  Sugar and saccharin content of antacids. , 1981 .

[3]  G. Riegger,et al.  Antidiuretic hormone in congestive heart failure. , 1982, The American journal of medicine.

[4]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[5]  R. Anderson,et al.  Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. , 1985, Annals of internal medicine.

[6]  P. Reddy,et al.  Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. , 1985, The American journal of physiology.

[7]  T. Ryan,et al.  Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. , 1986, Journal of the American College of Cardiology.

[8]  M. Packer,et al.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.

[9]  J. Rouleau,et al.  Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. , 1986, Kidney international.

[10]  J. Cohn,et al.  Hemodynamic effects of infused arginine vasopressin in congestive heart failure. , 1986, Journal of the American College of Cardiology.

[11]  G. Francis,et al.  Arginine vasopressin and the renal response to water loading in congestive heart failure. , 1986, The American journal of cardiology.

[12]  A. Cowley,et al.  Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. , 1986, The Journal of clinical investigation.

[13]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[14]  Prognostic Value of Hyponatremia in Patients with Severe Chronic Heart Failure , 1990, Angiology.

[15]  G. Lamas,et al.  Activation of neurohumoral systems following acute myocardial infarction. , 1991, The American journal of cardiology.

[16]  S. Goldsmith.  Physiological arginine vasopressin levels do not enhance baroreflex function in normal humans. , 1994, The American journal of physiology.

[17]  L. Goldman,et al.  Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. , 1996, Archives of internal medicine.

[18]  R. Schrier,et al.  Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. , 1997, The Journal of clinical investigation.

[19]  M. Takanashi,et al.  Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.

[20]  S. Goldsmith.  Vasopressin: a therapeutic target in congestive heart failure? , 1999, Journal of cardiac failure.

[21]  W. Abraham,et al.  Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. , 1999, Journal of the American Society of Nephrology : JASN.

[22]  M. Burnier,et al.  Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects , 1999, European Journal of Clinical Pharmacology.

[23]  C. Johnston,et al.  Vasopressin receptor antagonism — a therapeutic option in heart failure and hypertension , 2000, Experimental physiology.

[24]  G. Robertson.  Antidiuretic hormone. Normal and disordered function. , 2001, Endocrinology and metabolism clinics of North America.

[25]  R. Schrier,et al.  Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. , 2001, Seminars in nephrology.

[26]  J. Frøkiaer,et al.  Physiology and pathophysiology of renal aquaporins. , 1999, Journal of the American Society of Nephrology : JASN.

[27]  Patrick J. Coles,et al.  The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. , 2001, Annual review of pharmacology and toxicology.

[28]  A. Martínez‐Castelao.  Lixivaptan (American Home Products). , 2001, Current opinion in investigational drugs.

[29]  R. Schrier,et al.  Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. , 2001, The Mount Sinai journal of medicine, New York.

[30]  J. Verbalis,et al.  Vasopressin V2 receptor antagonists. , 2001, Cardiovascular research.

[31]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[32]  A. Patat,et al.  Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites , 2002, Hepatology.

[33]  J. Verbalis.  Vasopressin V2 receptor antagonists. , 2002, Journal of molecular endocrinology.

[34]  R. Prescott,et al.  Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. , 2002, Journal of the American College of Cardiology.

[35]  C. Johnston,et al.  Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. , 2002, Cardiovascular research.

[36]  S. Goldsmith.  Vasopressin antagonists in CHF: ready for clinical trials? , 2002, Cardiovascular research.

[37]  S. Nielsen.  Renal aquaporins: an overview , 2002, BJU international.

[38]  M Emberton,et al.  The ‘top 10’ urological procedures: a study of hospital episodes statistics 1998–99 , 2002, BJU international.

[39]  J. Verbalis,et al.  Systemic diseases associated with disorders of water homeostasis. , 2002, Endocrinology and metabolism clinics of North America.

[40]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[41]  R. Schrier,et al.  Pathophysiological roles of arginine vasopressin and aquaporin‐2 in impaired water excretion , 2003, Clinical endocrinology.

[42]  C. O'connor,et al.  Vasopressin: a new target for the treatment of heart failure. , 2003, American heart journal.

[43]  M. Thibonnier.  Vasopressin receptor antagonists in heart failure. , 2003, Current opinion in pharmacology.

[44]  P. Thuluvath,et al.  A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.

[45]  Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans. , 2003, Clinical nephrology.

[46]  C. O'connor,et al.  The problem of decompensated heart failure: nomenclature, classification, and risk stratification. , 2003, American heart journal.

[47]  C. O'connor,et al.  Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial , 2004 .

[48]  M. Kawakami,et al.  Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. , 2004, Kidney international.

[49]  J. Verbalis,et al.  Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia , 2004 .

[50]  M. Gheorghiade,et al.  ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL , 2004 .

[51]  D. DeMets,et al.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). , 2005, Journal of cardiac failure.

[52]  S. Shoaf,et al.  Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias , 2005, Journal of cardiovascular pharmacology and therapeutics.

[53]  S. Goldsmith.  Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. , 2005, The American journal of cardiology.

[54]  J. Ghali,et al.  Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. , 2006, The Journal of clinical endocrinology and metabolism.

[55]  S. Goldsmith.  Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? , 2006, The American journal of medicine.

[56]  M. Gheorghiade,et al.  Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. , 2006, The American journal of cardiology.

[57]  S. Goldsmith.  Efficacy and Safety of Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study , 2006 .

[58]  W. Abraham,et al.  Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. , 2006, Journal of the American College of Cardiology.